Clinical Trial Update: Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture [Phase 1]

View source ↗

Summary

Phase 1 study evaluating intravenous HMM910, a human mesenchymal stem cell therapy, in postmenopausal women with osteoporosis at high fracture risk; the trial s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• HMM910

Snippet

Sponsor: HELP Therapeutics Co., Ltd. | Conditions: Osteoporosis in Post-menopausal Women, Osteoporosis | Phase 1 | Status: ACTIVE_NOT_RECRUITING